Alberta residents with neovascular (wet) age-related macular degeneration (AMD), the leading cause of vision loss over the age of 50, have received a dose of good news with the decision by Alberta Health and Wellness to reimburse the innovative treatment Lucentis* (ranibizumab) on the Alberta Blue Cross insurance plan.
Now people who are suffering from wet-age- related-macular-degeneration can improve there hyperopia (farsightedness). The ability to read a newspaper or even prepare a meal functions require near-vision . …
XOMA’s technologies and experienced team have contributed to the success of marketed antibody products, including LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for …
Ranibizumab was approved by the U.S. Provisions and Drug Administration for the treatment of patients with irresolute stage interconnected macular degeneration in June 2006. About JDRF. JDRF was founded in 1970 by the parents of …
To evaluate optical coherence tomography (OCT)-based intravitreal ranibizumab treatment for neovascular age-related macular degeneration (AMD), the charts of consecutive patients who received intravitreal ranibizumab for subfoveal …
